Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ciproxin Infusion 100mg/50ml solution for infusion bottles
0501120L0BBAEAB
|
Ciproxin | Ciprofloxacin | Infections | No data available |
|
Ciproxin Infusion 200mg/100ml solution for infusion bottles
0501120L0BBAFAD
|
Ciproxin | Ciprofloxacin | Infections | No data available |
|
Ciproxin Infusion 400mg/200ml solution for infusion bottles
0501120L0BBAGAY
|
Ciproxin | Ciprofloxacin | Infections | No data available |
|
Claforan 1g powder for solution for injection vials
0501021D0BBABAB
|
Claforan | Cefotaxime sodium | Infections | No data available |
|
Claforan 2g powder for solution for injection vials
0501021D0BBACAC
|
Claforan | Cefotaxime sodium | Infections | No data available |
|
Claforan 500mg powder for solution for injection vials
0501021D0BBAAAA
|
Claforan | Cefotaxime sodium | Infections | No data available |
|
Clamelle 500mg tablets
0501050A0BCAAAD
|
Clamelle | Azithromycin | Infections | No data available |
|
Clarie XL 500mg tablets
0501050B0BEAAAE
|
Clarie | Clarithromycin | Infections | No data available |
|
Clarithromycin 125mg granules for oral suspension sachets
0501050B0AAAGAG
|
Clarithromycin | Clarithromycin | Infections | No data available |
|
Clarithromycin 125mg granules for oral suspension straws
0501050B0AAAKAK
|
Clarithromycin | Clarithromycin | Infections | No data available |
|
Clarithromycin 187.5mg granules for oral suspension straws
0501050B0AAALAL
|
Clarithromycin | Clarithromycin | Infections | No data available |
|
Clarithromycin 250mg granules for oral suspension straws
0501050B0AAAMAM
|
Clarithromycin | Clarithromycin | Infections | No data available |
|
Clarosip 125mg granules for oral suspension straws
0501050B0BDAAAK
|
Clarosip | Clarithromycin | Infections | No data available |
|
Clarosip 187.5mg granules for oral suspension straws
0501050B0BDABAL
|
Clarosip | Clarithromycin | Infections | No data available |
|
Clarosip 250mg granules for oral suspension straws
0501050B0BDACAM
|
Clarosip | Clarithromycin | Infections | No data available |
|
Clindamycin 100mg/5ml oral suspension
0501060D0AAATAT
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 120mg/5ml oral solution
0501060D0AAAJAJ
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 150mg/5ml oral solution
0501060D0AAAHAH
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 150mg/5ml oral suspension
0501060D0AAAQAQ
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 200mg/5ml oral suspension
0501060D0AAARAR
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 20mg/5ml oral solution
0501060D0AAAFAF
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 300mg/5ml oral solution
0501060D0AAAGAG
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 400mg/5ml oral solution
0501060D0AAAIAI
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 450mg/5ml oral solution
0501060D0AAAPAP
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
|
Clindamycin 50mg/5ml oral suspension
0501060D0AAASAS
|
Clindamycin hydrochloride (Systemic) | Clindamycin hydrochloride | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.